LIR-8 Inhibitors
Chemical inhibitors of LIR-8 operate through various mechanisms to impede its function within cellular signaling pathways. Cyclosporin A and FK506 (Tacrolimus) target the calcineurin pathway. Both chemicals bind to their respective immunophilins (cyclophilins for Cyclosporin A and FKBP12 for FK506) to form complexes that inhibit the phosphatase activity of calcineurin. This inhibition prevents the dephosphorylation and subsequent activation of NFAT transcription factors, which are crucial for the transduction of signals that may involve LIR-8 in modulating immune responses. Similarly, Rapamycin (Sirolimus) binds to FKBP12 but diverges to inhibit mTOR, a kinase that serves as a central regulator of cell growth and metabolism, including that of immune cells. The inhibition of mTOR can suppress the cellular processes that LIR-8 may influence.
Continuing with the theme of kinase inhibition, PP2 and Dasatinib obstruct Src family kinases, while SP600125 targets the JNK enzyme, and SB203580 specifically inhibits p38 MAP kinase. Src family kinases, JNK, and p38 MAP kinase are all pivotal components of receptor-mediated signaling cascades, and their obstruction can disrupt the downstream signaling that potentially involves LIR-8. Moreover, PD98059 and U0126, as MEK inhibitors, and LY294002 and Wortmannin, as PI3K inhibitors, restrict the MAPK/ERK and PI3K/AKT pathways, respectively. The MAPK/ERK pathway is integral to the proliferation and differentiation of immune cells, and PI3K/AKT signaling is fundamental to cell survival and function. The inhibition of these kinases by the aforementioned chemicals can impede the pathways that LIR-8 would normally engage in to carry out its role in the immune system. Lastly, Ibrutinib's inhibition of Bruton's tyrosine kinase, a key enzyme in B cell receptor signaling, can also indirectly hinder the functional activity of LIR-8 by suppressing the B cell signaling that could be associated with LIR-8's regulation of immune responses.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A is an immunosuppressant that binds to the cyclophilins which inhibits calcineurin. Since LIR-8 is involved in immune response modulation, inhibiting calcineurin can lead to decreased activation of NFAT transcription factors, thereby inhibiting the signaling cascades in which LIR-8 is involved. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
FK506 binds to FKBP12, creating a complex that inhibits calcineurin. By inhibiting calcineurin, FK506 leads to reduced activation of NFAT controlled genes, which include those involved in the immune response pathways where LIR-8 plays a role. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12, but instead of affecting calcineurin, it inhibits mTOR. Since mTOR signaling is essential for certain aspects of immune cell function, this inhibition can suppress the pathways crucial for the functional activity of LIR-8. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. Src kinases are involved in the activation of various cell surface receptors, and inhibiting them can disrupt downstream signaling pathways that LIR-8 may utilize to exert its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor which prevents the activation of ERK, part of the MAPK pathway. LIR-8, through its role in immune responses, may signal through MAPK, and inhibiting MEK can therefore inhibit the functional activity of LIR-8. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, preventing the phosphorylation and activation of AKT. Given that PI3K/AKT pathway can regulate immune cell function, inhibiting PI3K can indirectly inhibit LIR-8 by limiting its downstream signaling cascade. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, which irreversibly inhibits the enzyme, leading to reduced AKT signaling. Inhibition of this pathway can suppress the functional activity of LIR-8 as it is implicated in the regulation of immune responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which is involved in inflammatory responses. By inhibiting p38 MAP kinase, SB203580 can disrupt signaling pathways that LIR-8 may signal through, thereby inhibiting its activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor, which has broad specificity, including Src family kinases. It can inhibit signaling pathways that are essential for the functional activity of LIR-8 in immune responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathway. By inhibiting JNK, SP600125 can suppress the pathway's influence on immune response, potentially inhibiting the function of LIR-8. | ||||||